Monashee Investment Management LLC Has $4.38 Million Stake in Compass Therapeutics, Inc. $CMPX

Monashee Investment Management LLC grew its position in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 657.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,250,000 shares of the company’s stock after acquiring an additional 1,085,000 shares during the period. Compass Therapeutics accounts for 2.2% of Monashee Investment Management LLC’s portfolio, making the stock its 17th largest holding. Monashee Investment Management LLC owned about 0.90% of Compass Therapeutics worth $4,375,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. grew its position in Compass Therapeutics by 45.6% during the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock worth $24,720,000 after acquiring an additional 2,212,794 shares during the last quarter. Vivo Capital LLC boosted its stake in Compass Therapeutics by 70.0% in the second quarter. Vivo Capital LLC now owns 6,043,466 shares of the company’s stock worth $15,713,000 after purchasing an additional 2,487,443 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its holdings in shares of Compass Therapeutics by 11.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock worth $11,505,000 after purchasing an additional 449,868 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Compass Therapeutics by 22.8% in the third quarter. Rhumbline Advisers now owns 139,313 shares of the company’s stock valued at $488,000 after buying an additional 25,826 shares in the last quarter. Finally, Alps Advisors Inc. raised its holdings in shares of Compass Therapeutics by 11.3% in the third quarter. Alps Advisors Inc. now owns 83,007 shares of the company’s stock valued at $291,000 after buying an additional 8,410 shares during the last quarter. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Trading Down 2.2%

Shares of NASDAQ CMPX opened at $5.65 on Friday. Compass Therapeutics, Inc. has a 1 year low of $1.33 and a 1 year high of $6.88. The firm’s 50-day moving average is $5.86 and its 200-day moving average is $4.72. The firm has a market capitalization of $1.00 billion, a PE ratio of -12.56 and a beta of 1.46.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on CMPX shares. William Blair assumed coverage on shares of Compass Therapeutics in a report on Monday, January 5th. They set an “outperform” rating on the stock. Raymond James Financial reiterated an “outperform” rating and set a $9.00 target price on shares of Compass Therapeutics in a research report on Tuesday, January 6th. Citizens Jmp set a $10.00 price target on shares of Compass Therapeutics in a report on Wednesday, December 3rd. Citigroup initiated coverage on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. They issued an “outperform” rating for the company. Finally, Wall Street Zen raised Compass Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 16th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $13.36.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.